Training in and Experience with Endobronchial Ultrasound

Christina R. Bellinger a Arjun B. Chatterjee a Norman Adair a Tim Houle a
Irtaza Khan b Edward Haponik a

a Department of Pulmonary/Critical Care, Wake Forest Baptist Health, and b Salem Chest, Winston Salem, N.C., USA

Key Words
Adequate specimen sampling · Endobronchial ultrasound · Lymphadenopathy · Procedural yield · Transbronchial needle aspiration

Abstract
Background: Diagnosing mediastinal and hilar lymphadenopathy and staging lung cancer with endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) are on the rise, but uncertainty surrounds the optimal number of cases needed to achieve acceptable yields. Objectives: To determine the threshold at which EBUS-TBNA reaches adequate yields among trainees and skilled bronchoscopists. Methods: We reviewed all EBUS-TBNAs performed at our medical center since implementing the use of EBUS (n = 222). Results: EBUS-TBNAs were performed in 222 patients (344 nodes). The percentage of adequate specimens sampled (diagnostic specimens or nodal tissue) rose from 66% in 2008 to 90% in 2012 (p < 0.01) and cancer yield improved from 34% in 2008 to 48% in 2012 (p < 0.01). Attending physicians who performed an average of more than 10 procedures per year had higher yields compared to those who performed fewer than 10 procedures per year (86 vs. 68%, p < 0.01). The yield of trainees also improved with every 10 procedures (79, 90 and 95%, p < 0.001) and that of attending physicians with experience (1–25 procedures: 78% yield, 26–50 procedures: 87% yield and 50+ procedures: 90% yield; p < 0.01). Among trainees, failure rates declined steadily. Conclusion: EBUS-TBNA yield (malignant and benign) increases with increasing experience amongst experienced bronchoscopists and trainees as early as the first 20–25 procedures. Pulmonary trainees had a rapid decline in failure rates. These findings suggest that in an academic environment a minimum of 20–25 procedures is needed to achieve acceptable yields.

Introduction
Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) is an increasingly effective method for sampling mediastinal and hilar lymph nodes [1, 2]. Although primarily employed for lung cancer staging, this technology is also capable of diagnosing both benign and malignant lung node pathologies. Yields of EBUS-TBNA vary from 89 to 96% at skilled centers [3–6]. The learning curve for this relatively new diagnostic tool has not been clearly delineated. The American Col-
lege of Chest Physicians recommends 50 procedures for competency [7], but this recommendation was made for radial EBUS before real-time linear EBUS became widespread. Kemp et al. [8] performed a cusum analysis of 500 EBUS-TBNAs performed by five operators. The speed of attaining high yields ranged from immediately to not even within the first 100 procedures. An Australian study found that diagnostic sensitivity increased from 60–80% in the first 20 cases to 92–93% after 20 cases [9]. A group of thoracic surgeons found that their diagnostic accuracy improved markedly (from 50 to 95.6%) after just 10 procedures [10]. Another surgery group reduced false-negative and nondiagnostic samples to <10% after 22 cases [11]. Most recently, Wahidi et al. [12] noted that after a didactic curriculum, simulation practice and 13 procedures, trainees were able to navigate the airways, identify the lymph node of interest and perform successful EBUS-TBNA. With such variability, it is no wonder the debate over what number is needed to achieve proficiency continues [13, 14] and whether that number differs between trainees and attending physician bronchoscopists. To address this concern, we evaluated the learning curve of EBUS at an academic teaching institution.

**Methods**

**Study Design**

Following approval from the Institutional Review Board at Wake Forest University (ID IRB00013684), we reviewed EBUS procedures performed at Wake Forest Baptist Health since implementing its use in 2008 and extending over a 5-year period. We reviewed medical records with regard to patient age, gender, sedation used, procedure time, recovery time, diagnosis and attending and trainee bronchoscopist participation.

**Methods**

EBUS-TBNA was performed using an Olympus® BF-Convex Scope XBF-UC160 F-OL8 with a 22-gauge needle or Pentax® Convex Scope EB-1970UK with a 22-gauge cytology needle. Attending physicians were experienced bronchoscopists (mean experience: 13 years), many with extensive conventional TBNA (cTBNA) experience [15]. Moderate sedation employed titrated doses of fentanyl and midazolam. General anesthesia involved either a laryngeal airway or endotracheal tube as determined by the bronchoscopist and anesthesiologist. Needle aspirates were prepared in the bronchoscopy suite and rapid on-site cytology was used. If the sample was likely non-small cell lung cancer, then nodal survey and staging was performed by sampling according to the 7th edition of the TNM staging [16] (N3 then N2 then N1) followed by a cell block to provide additional material for immunohistochemical staining and subclassification. Malignancy yield was defined if lung or metastatic cancer was described by pathology. Adequate specimens encompassed all malignancy, lymph tissue or granulomas (in patients with a final clinical diagnosis of sarcoidosis).

Trainees of all levels were allowed to perform EBUS. They had no prior EBUS simulation training but had attended a 1-day general bronchoscopy course. An advanced bronchoscopy fellow, who focuses on additional training in advanced diagnostic bronchoscopy, is present in the majority of cases. Often, the fellow(s) perform the entire procedure unless difficulties occur requiring the attending bronchoscopist to take the instrument.

**Analyses**

Analyses were performed comparing EBUS-TBNA yield by year, lymph node location, operator experience and type of sedation. Results are presented as percentages and means ± SD. Continuous variables were compared among groups using ANOVA models and, where a signal was present, groups were compared with Wilcoxon tests. Nominal variables were analyzed using χ² tests for association followed by nominal logistic evaluation when applicable. Results were considered significant when p ≤ 0.05.

**Results**

**Patient Demographic Characteristics**

Between January 2008 and December 2012, a total of 222 EBUS-guided bronchoscopies were performed targeting 344 nodes. Mean patient age was 63 ± 12 years and the majority of patients were male (59%; table 1).

**Bronchoscopy Characteristics**

Typically, procedures were performed in an outpatient setting (84%). With progressive institutional experience, moderate sedation was replaced in favor of general anesthesia (2008: 86% moderate sedation vs. 14% general anesthesia, 2012: 2% moderate sedation vs. 98% general anesthesia, p < 0.001). Over the course of experience, there was no difference in anesthesia time (2008: mean 84 ± 22
min, 2012: mean 86 ± 17 min, p = 0.12) or procedure time (2008: mean 38 ± 12 min, 2012: mean 48 ± 20 min, p = 0.63; table 1). Procedure time was shorter when the advanced bronchoscopy fellow was the primary operator (38 ± 14 vs. 43 ± 16 min, p < 0.05).

**Lymph Node Characteristics**

Of the 222 EBUS-TBNAs performed, 344 nodes were biopsied (1.5 nodes per procedure). There was an increase in the number of nodes sampled per procedure from 2008 to 2012 (from 1.3 to 1.6). Nodal stations biopsied were 4R (38%), 7S (25%), 11R (11%), 4L (9%) and 10R (6%). The number of hilar nodes aspirated increased from 13% in 2008 to 34% in 2012 (p < 0.01). Mean node size biopsied was 16 ± 7 mm (table 2).

**Pathology and Diagnosis**

Cytopathology of the lymph node aspirates revealed an improvement in yield over time. Cancer yield increased from 34% in 2008 to 48% in 2012 (p < 0.01). The majority of malignant aspirates were non-small cell carcinomas (74%). Small cell lung cancer comprised 13% of the samples. Lymphoid tissue indicating successful nodal sampling but without a pathologic diagnosis was seen in 28% of the EBUS-TBNAs. Overall, 14% of EBUS-TBNAs had an unsatisfactory sample (not representative of nodal tissue), but that frequency decreased over time (from 24% in 2008 to 7% in 2012, p = 0.17). Adequate specimens, in which either a diagnostic specimen or lymphoid tissue was obtained, were retrieved in 83%. Larger nodes tended to have higher cancer yields; mean node size for malignancy was 19 ± 8 mm compared to 14 ± 5 mm for nonmalignant and unsatisfactory samples (p < 0.01). Adequate specimen retrieval increased from 66% in 2008 to 90% in 2012 (p < 0.01). Use of general anesthesia was associated with higher adequate specimen retrieval (78% for moderate sedation vs. 85% for general anesthesia, p < 0.01) and sampling of smaller nodes (18 ± 8 vs. 15 ± 7 mm, p = 0.02). Cancer yield did not differ with the type of sedation (45% for moderate sedation vs. 44% for general anesthesia, p = 0.40).

**EBUS Learning Curve**

EBUS-TBNA yield varied with operator experience. For attending bronchoscopists, overall yield improved with every 25 procedures: from 78 to 87 to 90% (fig. 1; p < 0.01). Bronchoscopists who performed on average more than 10 EBUS per year had a higher specimen adequacy (85 vs. 68%, p = 0.01) and cancer yield (46 vs. 35%, p < 0.01; fig. 2). Trainees of every year of fellowship were allowed to perform the procedure with direct attending su-

---

**Table 2. Lymph node characteristics**

<table>
<thead>
<tr>
<th>ATS station</th>
<th>% (n)</th>
<th>Node size, mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>2L</td>
<td>1% (2)</td>
<td>13±1</td>
</tr>
<tr>
<td>2R</td>
<td>4% (15)</td>
<td>13±6</td>
</tr>
<tr>
<td>4L</td>
<td>9% (32)</td>
<td>15±4</td>
</tr>
<tr>
<td>4R</td>
<td>38% (130)</td>
<td>17±8</td>
</tr>
<tr>
<td>7</td>
<td>25% (86)</td>
<td>16±7</td>
</tr>
<tr>
<td>10L</td>
<td>2% (6)</td>
<td>24±12</td>
</tr>
<tr>
<td>10R</td>
<td>6% (22)</td>
<td>15±5</td>
</tr>
<tr>
<td>11L</td>
<td>1% (5)</td>
<td>21±6</td>
</tr>
<tr>
<td>11R</td>
<td>11% (38)</td>
<td>16±6</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>16±7</td>
</tr>
</tbody>
</table>

ATS = American Thoracic Society. Means ± SD and % (n).
pervision. First-year trainees performed 24% of procedures, 2nd-year fellows performed 31% of procedures and 3rd-year trainees performed 44% of procedures. Yield improved with each year of training: 1st: 79% adequate/44% cancer, 2nd: 84% adequate/43% cancer, 3rd: 85% adequate/48% cancer (1st vs. 3rd year, p < 0.01 for specimen adequacy and p = 0.01 for cancer yield). Individual trainees improved their yield after every 10 procedures: from 79% (41% cancer yield) to 90% (54% cancer yield) to 95% (58% cancer yield; p < 0.01 for adequacy and p = 0.03 for cancer yield; fig. 3; table 3). An advanced bronchoscopy fellow was the primary operator in almost half of the procedures (46%), and his/her yield was higher than that of other trainees (88 vs. 79%, p < 0.01). The difference was not due to an increase in cancer yield (52 vs. 48%, p = 0.76) but rather to fewer unsatisfactory samples (10% for the advanced bronchoscopy fellows vs. 18% for other fellows, p = 0.05).

Failure rates – defined as insufficient or unsatisfactory samples according to cytopathology – were analyzed using a generalized linear model. Rising procedural numbers correlated with falling failure rates (p = 0.02; fig. 4). When adjusted for the type of sedation, average node size and year the procedure was performed, the fall in the failure rate is still statistically significant (p = 0.05, 95% CI 0.889–1.000).

**Table 3. Yield by procedure number**

<table>
<thead>
<tr>
<th>Procedures performed</th>
<th>Attending bronchoscopists, procedures, adequate specimen, %</th>
<th>p value</th>
<th>Trainees bronchoscopists, procedures, adequate specimen, %</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–10</td>
<td>8, 53, 70</td>
<td>0.11</td>
<td>25, 146, 79</td>
<td>0.08</td>
</tr>
<tr>
<td>11–20</td>
<td>5, 43, 84</td>
<td>&lt;0.01</td>
<td>10, 48, 90</td>
<td>0.06</td>
</tr>
<tr>
<td>21–30</td>
<td>4, 32, 94</td>
<td>0.44</td>
<td>3, 19, 95</td>
<td>0.17</td>
</tr>
<tr>
<td>31–40</td>
<td>4, 35, 89</td>
<td>0.03</td>
<td>1, 4, 100</td>
<td></td>
</tr>
<tr>
<td>41–50</td>
<td>3, 27, 78</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51–60</td>
<td>2, 12, 100</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 3.** Trainee learning curve with EBUS-TBNA: yield steadily rises with each procedure performed by trainees.

**Fig. 4.** Fall in failure rate among trainees with each EBUS-TBNA performed. Unadjusted p = 0.02. When adjusted for the type of sedation, average node size and year the procedure was performed, the fall in the failure rate is still statistically significant (p = 0.05, 95% CI 0.889–1.000).
**Discussion**

The overall EBUS-TBNA yield in this report is consistent with that at skilled centers (89–95%) [3–6]. The cancer yield and specimen adequacy improved with experience. Yields rose over 5 years with increasing institutional experience. The bronchoscopists who performed more EBUS per year had higher yields than those who performed fewer procedures, consistent with previously described learning curves for EBUS-TBNA and other bronchoscopic sampling procedures [12, 17, 18]. Yield improved significantly after 20 and 25 bronchoscopies among trainees and skilled bronchoscopists, respectively. Yield rose with each trainee year, and the advanced bronchoscopy trainee achieved higher specimen adequacy with shorter procedure time compared to other trainees. Failure rates declined with each procedure performed. This study is consistent with the range of other demonstrations of learning curves ranging from 10 to 50 procedures [9–12], but this study is the first to analyze the performance of both experienced bronchoscopists and trainees over a prolonged time. Similar to other reports, use of general anesthesia correlated with improved lymph node sampling [17, 19].

The number of procedures performed over this 5-year review (n = 222) is less than some centers perform over the course of 1 year. This is because we reserve EBUS for sampling of smaller nodes and cancer staging (mean 16 ± 7 mm, median 14 mm). Larger adenopathy and masses are sampled with cTBNA (n = 209 from 2009 to 2010) as our yield with this modality when targeting larger nodes is high (86% yield, mean size 21 ± 11 mm) [16]. Using the complementarity of cTBNA and EBUS spares patients the higher cost of EBUS [16, 20]. Reserving smaller nodes and staging for EBUS may explain why our yields are lower than at some centers. If EBUS were used in ‘all comers’ with mediastinal and hilar lymphadenopathy we would anticipate higher EBUS yields. We did not appraise the effects of trainee familiarity and performance of cTBNA upon their EBUS learning curves nor did we evaluate the impact of virtual reality simulation [21, 22]. Each of these factors might further enhance trainee EBUS performance.

This retrospective study is limited in that we cannot divide which samples were specifically obtained by the trainee and which samples were obtained by the attending bronchoscopist. It is our practice that we gradually give advancing fellows more independence. Attending physicians are more likely to sample concurrently with 1st- and 2nd-year trainees, while they may observe 3rd-year trainees and the advanced bronchoscopy fellow without taking the bronchoscope. Since we use on-site cytology, attending physicians are more likely to participate in specimen acquisition if the first few passes are negative.

The progressive increase in yield in EBUS-TBNA is similar to that observed with cTBNA (i.e. guided by pre-procedural computed tomography rather than real-time imaging). Malignancy yields improved from 21 to 48% over a 3-year review after increasing procedural volume, trainee education and alterations in aspiration techniques [20]. Following initiation of cTBNA, Hsu et al. [23] reported improved yields over a 3.5-year period (p = 0.03). After analyzing yields of TBNA, another site concluded that 50 procedures were required to achieve proficiency [24], while other facilities improved yield from 19 to 88% (p < 0.001) [25] and 46 to 85% (p = 0.09) [26] over an 18-month and 1-year self-learning period, respectively. Hermens et al. [27] reported improved TBNA yields from 77 to 87% after 32 months of experience. More recently, another center demonstrated yields improving from 72 to 96% after an observational education program [28]. A systematic review of cTBNA revealed that sensitivity rose with rising bronchoscopist experience [29].

Our study has important implications for training and credentialing. While the yield was higher for the advanced bronchoscopy fellow, this training was not essential to achieving acceptable EBUS yields. As part of their comprehensive education, we emphasize the need for all bronchoscopy trainees to learn EBUS.

**Conclusions**

In an academic environment with intense supervision and training and established use of conventional TBNA, EBUS-TBNA yield improves after 20 and 25 procedures in experienced bronchoscopists and trainees, respectively. Failure rates declined with each trainee procedure. Our data and other studies suggest that a minimum of 20–25 procedures are needed to significantly raise yields. This is below the minimum of 50 recommended by the American College of Chest Physician expert opinion guidelines for competency [7]. In addition, these data suggest that maintenance of procedural skills for EBUS-TBNA may be at least 10 procedures per year to preserve higher yields.

**Disclosure Statement**

No conflicts of interest.
References

1 Gompelmann D, Herth FJF: Role of endobronchial and endoscopic ultrasound in pulmonary medicine. Respiration 2014;87:3–8.


